|
Q2 FY2027
As of Sep 30, 2026
|
Q1 FY2027
As of Jun 30, 2026
|
Q4 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Mar 31, 2021
|
Q4 FY2020
As of Mar 31, 2020
|
Q4 FY2019
As of Mar 31, 2019
|
Q4 FY2018
As of Mar 31, 2018
|
Q4 FY2017
As of Mar 31, 2017
|
Q4 FY2016
As of Mar 31, 2016
|
Q4 FY2015
As of Mar 31, 2015
|
Q4 FY2014
As of Mar 31, 2014
|
Q4 FY2013
As of Mar 31, 2013
|
Q4 FY2012
As of Mar 31, 2012
|
Q4 FY2011
As of Mar 31, 2011
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||
| Current assets: | ||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||
| Restricted cash and cash equivalents - Asbestos | ||||||||||||||||||
| Restricted cash and cash equivalents | ||||||||||||||||||
| Restricted short-term investments — Asbestos | ||||||||||||||||||
| Accounts and other receivables, net | ||||||||||||||||||
| Inventories | ||||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||||
| Insurance receivable - Asbestos | ||||||||||||||||||
| Workers’ compensation - Asbestos | ||||||||||||||||||
| Assets held for sale | ||||||||||||||||||
| Total current assets | ||||||||||||||||||
| Property, plant and equipment, net | ||||||||||||||||||
| Operating lease right-of-use assets | ||||||||||||||||||
| Finance lease right-of-use assets | ||||||||||||||||||
| Goodwill | ||||||||||||||||||
| Intangible assets, net | ||||||||||||||||||
| Restricted long-term investments - Asbestos | ||||||||||||||||||
| Insurance receivable - Asbestos | ||||||||||||||||||
| Workers’ compensation - Asbestos | ||||||||||||||||||
| Deferred income taxes | ||||||||||||||||||
| Deferred income taxes — Asbestos | ||||||||||||||||||
| Other assets | ||||||||||||||||||
| Total assets | ||||||||||||||||||
| Liabilities and Shareholders’ Equity | ||||||||||||||||||
| Current liabilities: | ||||||||||||||||||
| Accounts payable and accrued liabilities | ||||||||||||||||||
| Accrued payroll and employee benefits | ||||||||||||||||||
| Operating lease liabilities | ||||||||||||||||||
| Finance lease liabilities | ||||||||||||||||||
| Long-term debt, current portion | ||||||||||||||||||
| Accrued product warranties | ||||||||||||||||||
| Income taxes payable | ||||||||||||||||||
| Asbestos liability | ||||||||||||||||||
| Workers’ compensation - Asbestos | ||||||||||||||||||
| Liabilities held for sale | ||||||||||||||||||
| Other liabilities | ||||||||||||||||||
| Total current liabilities | ||||||||||||||||||
| Long-term debt | ||||||||||||||||||
| Deferred income taxes | ||||||||||||||||||
| Operating lease liabilities | ||||||||||||||||||
| Finance lease liabilities | ||||||||||||||||||
| Accrued product warranties | ||||||||||||||||||
| Income taxes payable | ||||||||||||||||||
| Asbestos liability | ||||||||||||||||||
| Workers’ compensation - Asbestos | ||||||||||||||||||
| Other liabilities | ||||||||||||||||||
| Total liabilities | ||||||||||||||||||
| Shareholders’ equity: | ||||||||||||||||||
| Common stock, Euro 0.59 par value, 2.0 billion shares authorized; 581,588,392 shares issued and outstanding at September 30, 2026 and 580,174,308 shares issued and outstanding at March 31, 2026 | ||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||
| Retained earnings | ||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||
| Total shareholders’ equity | ||||||||||||||||||
| Total liabilities and shareholders’ equity | ||||||||||||||||||
Loading...